Entrada Therapeutics, Inc.
NASDAQ:TRDABiotechnology
+$0.03 today
- Market cap
- $196.93M
- Beta
- -0.26
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$3.97
Volume 0.82M
Average 0.36M
Income Statement
Follow revenue through to earnings.
Revenue
$25.42M
FY 2025 · Annual
-87.9% YoYOperating Income
-$156.00M
FY 2025 · Annual
Net Income
-$143.75M
FY 2025 · Annual
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 129.01M | 210.78M | 25.42M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 4.1M |
| Gross Profit | 0 | 0 | 129.01M | 210.78M | 21.33M |
| Gross Margin | — | — | 100.0% | 100.0% | 83.9% |
| Research & Development | 35.93M | 66.61M | 99.88M | 125.31M | 142.27M |
| Selling, General & Admin | 15.2M | 30.64M | 32.29M | 38.47M | 41.05M |
| Operating Expenses | 51.13M | 97.25M | 132.18M | 163.77M | 177.32M |
| Depreciation & Amortization | 1.12M | 1.9M | 2.84M | 3.77M | 425K |
| EBITDA | (50.04M) | (90.09M) | 14.9M | 70.26M | (142.4M) |
| EBITDA Margin | — | — | 11.5% | 33.3% | -560.2% |
| Operating Income | (51.13M) | (97.25M) | (3.16M) | 47.01M | (156M) |
| Operating Margin | — | — | -2.5% | 22.3% | -613.7% |
| Interest Income | 0 | 2.63M | 15.22M | 19.47M | 0 |
| Interest Expense | 0 | 2.63M | 0 | 0 | 0 |
| Other Income / Expenses | (31K) | 2.63M | 15.22M | 19.47M | 13.17M |
| Income Before Tax | (51.16M) | (94.62M) | 12.06M | 66.49M | (142.83M) |
| Pre-Tax Margin | — | — | 9.3% | 31.5% | -561.8% |
| Income Tax Expense | 0 | 0 | 18.74M | 859K | 924K |
| Net Income | (51.16M) | (94.62M) | (6.69M) | 65.63M | (143.75M) |
| Net Margin | — | — | -5.2% | 31.1% | -565.5% |
| EPS (Basic) | (1.60) | (2.79) | (0.20) | 1.76 | (3.47) |
| EPS (Diluted) | (1.60) | (2.79) | (0.20) | 1.68 | (3.47) |
| 31.22M | 31.29M | 33.05M | 37.31M | 41.37M | |
| 31.22M | 31.29M | 33.05M | 39M | 41.37M |
TRDA Earnings Waterfall · TTM
NASDAQ:TRDA · Revenue to Net Income
Key Ratios
Analysis
$5.7M of revenue converted into -$166.1M of net income for the selected period. Gross margin is -534.2% and net margin is -3124.7%, showing how much revenue survives after costs and taxes. EPS is $-4.00, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| 8-K | Current report | Oct 14, 2026 | |
| SC 13D/A | SC 13D/A filing | Sep 10, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 9, 2026 |
How much revenue does TRDA generate?
Entrada Therapeutics, Inc. (TRDA) reported $25.42M of revenue in fiscal 2025.
Is TRDA profitable?
Entrada Therapeutics, Inc. (TRDA) reported -$143.75M of net income, with a net margin of -565.5%.
Continue the stock analysis
Jump to another research area for this company.